Teijin Limited (Teijin) and JCR Pharmaceuticals Co., Ltd. (JCR) announced that they have decided to terminate their co-development and Japan licensing agreement aimed at developing JTR-161, an allogeneic regenerative medical product containing dental pulp stem cells (DPCs) for the intended purpose of helping patients recover from acute cerebral infarctions (strokes). Using DPC isolated from human teeth extraction bodies, JTR-161 was expected to effectively suppress inflammation through immune regulatory factors and stimulate organ regeneration through trophic factors. JCR and Teijin signed their agreement in July 2017 and launched Japan-based Phase I/II clinical trials in 2019 to examine the safety and efficacy of intravenously administering JTR-161 to patients who have suffered acute cerebral infarction.

The primary endpoint was not achieved, however, so the two companies have decided to terminate their agreement and cease joint development And Teijin will return its Japan rights to JCR.